F8 and hemophilia A: Recently, peptide immunotherapy has been tested in preclinical models of hemophilia A (HA) (Pletinckx et al., 2022), which is an X-linked genetic disorder caused by mutations of coagulation factor VIII (FVIII) (Mannucci and Franchini, 2014).